Insights on REMS Programs and Strategies for Effective Patient Care

Opinion
Video

The panel provides an overview of REMS programs for bispecific therapies in multiple myeloma and discusses how institutions can educate healthcare professionals outside of oncology.

Recent Videos
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Related Content